Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06626919 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

A Phase 1 study of Myasthenia Gravis and Autoimmune Diseases, sponsored by Arcellx.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
13
Study locations

NCT06626919 is a Phase 1 study of Myasthenia Gravis and Autoimmune Diseases that is actively recruiting participants, run by Arcellx. The registered enrollment target is 30 participants, below the 190-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (84% lower). The trial reports 13 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06626919, a Phase 1 study of Myasthenia Gravis and Autoimmune Diseases, is actively recruiting participants, sponsored by Arcellx.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
13
Study locations

Study Summary

A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.

Conditions Studied

Myasthenia Gravis Autoimmune Diseases Muscle Weakness Neuromuscular Manifestations Muscular Diseases Autoimmune Diseases of the Nervous System Autoimmune

Interventions

  • BIOLOGICAL anito-cel
  • DRUG Standard Lymphodepletion regimen

Study Locations (13)

California

  • UCLA Medical Center - Los Angeles
  • University of California, Irvine - Orange
  • Stanford Hospital - Palo Alto

Minnesota

  • University of Minnesota Delaware Clinical Research Unit - Minneapolis
  • Mayo Clinic - Rochester

Texas

  • UT Southwestern Medical Center - Dallas
  • Houston Methodist Hospital - Houston

Florida

  • University of South Florida - Carol and Frank Morsani Center of Advanced Healthcare - Tampa

Michigan

  • Karmanos Cancer Institute - Detroit

New York

  • Columbia University Irving Medical Center - New York

Ohio

  • Ohio State University - Columbus

Oregon

  • Oregon Health & Science University (OHSU) - Portland

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-04-30
Est. Completion 2028-04
Phase Phase 1

Sponsor

Arcellx

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06626919

The ClinicalTrials.gov registry entry for NCT06626919 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (84% lower). The listed sponsor is Arcellx, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which anito-cel is the first listed.

NCT06626919 reports 13 study locations spanning 9 distinct geographic areas - top geographies include California, Minnesota, Texas.

Frequently Asked Questions

What is clinical trial NCT06626919 about?

NCT06626919 is a clinical study titled "A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases". A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.

What is the current status of trial NCT06626919?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-04-30. Estimated completion is 2028-04.

What conditions does trial NCT06626919 study?

This clinical trial studies the following conditions: Myasthenia Gravis, Autoimmune Diseases, Muscle Weakness, Neuromuscular Manifestations, Muscular Diseases.

What interventions are being tested in trial NCT06626919?

The interventions under investigation include: anito-cel (BIOLOGICAL), Standard Lymphodepletion regimen (DRUG).

Who is sponsoring clinical trial NCT06626919?

This trial is sponsored by Arcellx, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06626919 being conducted?

This trial has 13 study locations across California, Florida, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myasthenia Gravis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myasthenia Gravis

All registered trials for this condition

Autoimmune Diseases

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.